Ziopharm Oncology (ZIOP) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ziopharm Oncology Reports Financial Results for Fourth Quarter and Full Year 2019
March 2, 2020 4:05 PM ESTEmergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019
Balance sheet strengthened; cash of approximately $177 million funds operations to mid-2022
Clinical trial milestones and data readouts in 1H20
 Company to host conference call and webcast today at 4:30 p.m. ET
BOSTON, March 02, 2020 (GLOBE NEWSWIRE) --... More
